Everyone involved in the bapi trial was asked to sign a confidentiality agreement covering every aspect of the program. “You and your staff should refrain from commenting to third parties on the clinical trial or AAB-001 until the final analysis and trial results have been released to the public,” read one directive from the company sent to participants. “Analysts, hedge fund employees, investors, newspaper reporters and even other pharmaceutical representatives may contact you seeking trial-related information or your opinion about the expected results of the clinical trial.” Another warned:
...more
